Comparative study of quality of life, adverse effects after cytoreduction and HIPEC in stage IIIA-IIIC ovarian cancer

Nowadays cytorective surgery and HIPEC is the mainstay of management of advanced stages ovarian cancer. Study was conducted to assess the effectiveness of combined treatment in IIIA-IIIC ovarian cancer, its impact on quality of life. 37 patients of main group (CRS + HIPEC) were compared with 25 patients of control group (surgery + systemic chemotherapy). The quality of life was assessed with Medical Outcomes Study 36-Item Short Form Health Survey (SF-36). Comparative analysis of quality of life 6 months after treatment completion did not show significant statistical difference. Combination of cytoreduction with HIPEC improves quality of life in patients with ovarian cancer, is tolerated better and has less systemic toxicities than systemic chemotherapy

Optimal surgical treatment of locally advanced gynecological malignancies

The article presents our experience of advanced gynecological malignancies surgical treatment. We retrospectively analyzed 1215 cases of gynecological malignancies and selected 313 patients with locally advanced disease. All patients undergone surgical treatment in University Clinic of Odessa national medical university from 2006 till 2017. 32 HIPEC procedures were included in this study, 24 with cytoreduction. One-year survival was 88,6 % for cervical cancer, 85,2 % for ovarian cancer, 79,1 % for endometrial cancer. Five and ten year survival rate was 31 % and 14 % among ovarian cancer patients, 18 % and 9 % for ovarian cancer, 38 % and 18 % for endometrial cancer respectively. Cytoreduction with HIPEC were well tolerated with no perioperative mortality